Table 4.
Estimated annual economic and societal burden due to pneumococcal disease cases attributable to the serotypes included in PCV10, PCV13, PCV15, and PCV20 (in million USD).
| PCV13 NIP Countries | PCV10 NIP Countries | ||||
|---|---|---|---|---|---|
| Argentina | Mexico | Chile | Colombia | Brazil | |
| Economic burdena | |||||
| PCV10 serotypes | $2.13 | $8.73 | $0.25 | $1.89 | $1.98 |
| PCV13 serotypes | $3.59 | $87.28 | $2.07 | $19.60 | $25.33 |
| PCV15 serotypes | $3.93 | $87.28 | $2.55 | $19.60 | $26.34 |
| PCV20 serotypes | $5.50 | $122.44 | $3.06 | $20.35 | $30.91 |
| Societal burdenb | |||||
| PCV10 serotypes | $0.56 | $0.59 | $0.42 | $0.39 | $1.01 |
| PCV13 serotypes | $0.94 | $5.91 | $3.53 | $4.00 | $12.99 |
| PCV15 serotypes | $1.02 | $5.91 | $4.34 | $4.00 | $13.51 |
| PCV20 serotypes | $1.43 | $8.29 | $5.22 | $4.15 | $15.85 |
NIP, national immunization program; PCV, pneumococcal conjugate vaccine.
a
Economic burden inclusive of direct medical costs due to each pneumococcal disease state, including IPD, inpatient pneumonia, outpatient pneumonia, and OM.
b
Societal burden inclusive of indirect costs due productivity loss resulting from each pneumococcal disease state, including IPD, inpatient pneumonia, outpatient pneumonia, and OM.